Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04418947 · ClinicalTrials.gov registry record · NA
Project Resurgence Communication Trial
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 11,120
- Enrollment target
NCT04418947: Completed NA study, sponsored by University of Pennsylvania.
NCT04418947 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 11,120 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (693% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04418947, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,120 participants
- Enrollment target
Study Summary
Randomized, double-blind, of standard of care vs additional communication and factorial design of intervention letter vs. control letter and EHR vs mail delivery mechanism in patients who canceled visits and did not reschedule over a 90 day period starting March 9, 2020.
Interventions
- OTHER Communication type
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,120 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2020-07-17 |
| Phase | NA |
What the finished NCT04418947 record still lists
NCT04418947 is an interventional study that assigns participants to a tested intervention. Its 11,120 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (693% higher).
The record links to 0 conditions, and to 1 intervention - of which Communication type is the first listed.
NCT04418947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04418947 about?
NCT04418947 is a clinical study titled "Project Resurgence Communication Trial". Randomized, double-blind, of standard of care vs additional communication and factorial design of intervention letter vs. control letter and EHR vs mail delivery mechanism in patients who canceled visits and did not reschedule over a 90 day period starting March 9, 2020.
What is the current status of trial NCT04418947?
This trial is currently completed. It is a NA study. The enrollment target is 11,120 participants. The study started on 2020-06-15. Estimated completion is 2020-07-17.
What interventions are being tested in trial NCT04418947?
The interventions under investigation include: Communication type (OTHER).
Who is sponsoring clinical trial NCT04418947?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04418947's enrollment target sits among peer trials
11,120 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI